NO317628B1 - Iontoforetisk avlevering av en antimigrenemedisin - Google Patents

Iontoforetisk avlevering av en antimigrenemedisin Download PDF

Info

Publication number: NO317628B1
Authority: NO; Norway
Prior art keywords: formula; hydrogen; composition; active ingredient; radical
Prior art date: 1993-08-27

Application number

NO19960769A

Other languages

English (en)

Norwegian (no)

Other versions

NO960769D0 (no

NO960769L (no

Inventor

Jean Louis Mesens

Gustaaf Van Rett

Frank Maria Jozef De Beukelaar

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-27

Filing date

1996-02-26

Publication date

2004-11-29

1996-02-26 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1996-02-26 Publication of NO960769D0 publication Critical patent/NO960769D0/no

1996-04-23 Publication of NO960769L publication Critical patent/NO960769L/no

2004-11-29 Publication of NO317628B1 publication Critical patent/NO317628B1/no

Links

229940124433 antimigraine drug Drugs 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 48
239000000203 mixture Substances 0.000 claims abstract description 38
239000001257 hydrogen Substances 0.000 claims abstract description 24
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 24
239000002253 acid Substances 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 18
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 12
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 11
150000002431 hydrogen Chemical group 0.000 claims abstract description 10
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
-1 3,4-dihydro-2H-1-benzopyran-2-yl Chemical group 0.000 claims description 40
239000004480 active ingredient Substances 0.000 claims description 19
238000012377 drug delivery Methods 0.000 claims description 11
239000000872 buffer Substances 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
239000004332 silver Substances 0.000 claims description 9
229910021607 Silver chloride Inorganic materials 0.000 claims description 8
239000000463 material Substances 0.000 claims description 8
239000011159 matrix material Substances 0.000 claims description 8
229910052709 silver Inorganic materials 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 6
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 6
239000007853 buffer solution Substances 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
239000012528 membrane Substances 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
229920001059 synthetic polymer Polymers 0.000 claims description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 3
125000000304 alkynyl group Chemical group 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims 1
208000019695 Migraine disease Diseases 0.000 abstract description 5
206010027599 migraine Diseases 0.000 abstract description 5
150000002357 guanidines Chemical class 0.000 abstract description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
101100490437 Mus musculus Acvrl1 gene Proteins 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
239000003814 drug Substances 0.000 description 28
229940079593 drug Drugs 0.000 description 19
238000012360 testing method Methods 0.000 description 15
210000003491 skin Anatomy 0.000 description 13
150000003254 radicals Chemical class 0.000 description 11
239000000243 solution Substances 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 6
230000002460 anti-migrenic effect Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
239000002904 solvent Substances 0.000 description 5
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
235000010443 alginic acid Nutrition 0.000 description 4
229920000615 alginic acid Polymers 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
229930195733 hydrocarbon Natural products 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
229910052697 platinum Inorganic materials 0.000 description 4
229920001296 polysiloxane Polymers 0.000 description 4
229920002635 polyurethane Polymers 0.000 description 4
239000004814 polyurethane Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000009471 action Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000005684 electric field Effects 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000006260 foam Substances 0.000 description 3
239000012982 microporous membrane Substances 0.000 description 3
230000035515 penetration Effects 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
229930195734 saturated hydrocarbon Natural products 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
150000001805 chlorine compounds Chemical class 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
150000001860 citric acid derivatives Chemical class 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000010579 first pass effect Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
235000019426 modified starch Nutrition 0.000 description 2
150000002823 nitrates Chemical class 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
239000012811 non-conductive material Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
239000000419 plant extract Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
210000000434 stratum corneum Anatomy 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
125000006024 2-pentenyl group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
KBIWNQVZKHSHTI-UHFFFAOYSA-N 4-n,4-n-dimethylbenzene-1,4-diamine;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)C1=CC=C(N)C=C1 KBIWNQVZKHSHTI-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
229920000049 Carbon (fiber) Polymers 0.000 description 1
241001060815 Ceratonia Species 0.000 description 1
235000013913 Ceratonia Nutrition 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241001507921 Cydonia Species 0.000 description 1
235000009807 Cydonia Nutrition 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229920000569 Gum karaya Polymers 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
150000000994 L-ascorbates Chemical class 0.000 description 1
ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
BDYUSDIJIDGWCY-UHFFFAOYSA-N NN-Dimethyllauramide Chemical compound CCCCCCCCCCCC(=O)N(C)C BDYUSDIJIDGWCY-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
244000134552 Plantago ovata Species 0.000 description 1
235000003421 Plantago ovata Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002367 Polyisobutene Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
239000009223 Psyllium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000934878 Sterculia Species 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
108010055615 Zein Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
QVSXOXCYXPQXMF-UHFFFAOYSA-N alniditan Chemical compound C1CC2=CC=CC=C2OC1CNCCCNC1=NCCCN1 QVSXOXCYXPQXMF-UHFFFAOYSA-N 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229940009868 aluminum magnesium silicate Drugs 0.000 description 1
WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
239000004917 carbon fiber Substances 0.000 description 1
125000005587 carbonate group Chemical group 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
229940043431 ceratonia Drugs 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
239000004020 conductor Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000005370 electroosmosis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000011888 foil Substances 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000001288 gastroparesis Diseases 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
229910002804 graphite Inorganic materials 0.000 description 1
239000010439 graphite Substances 0.000 description 1
159000000011 group IA salts Chemical class 0.000 description 1
235000019314 gum ghatti Nutrition 0.000 description 1
KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
229910000271 hectorite Inorganic materials 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
235000010494 karaya gum Nutrition 0.000 description 1
239000000231 karaya gum Substances 0.000 description 1
229940039371 karaya gum Drugs 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000011133 lead Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
VLCAYQIMSMPEBW-UHFFFAOYSA-N methyl 3-hydroxy-2-methylidenebutanoate Chemical compound COC(=O)C(=C)C(C)O VLCAYQIMSMPEBW-UHFFFAOYSA-N 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001195 polyisoprene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
229940070687 psyllium Drugs 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
239000003542 rubefacient Substances 0.000 description 1
229940071089 sarcosinate Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
150000003377 silicon compounds Chemical class 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229940080236 sodium cetyl sulfate Drugs 0.000 description 1
229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000003351 stiffener Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
239000011135 tin Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Electrotherapy Devices (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

NO19960769A 1993-08-27 1996-02-26 Iontoforetisk avlevering av en antimigrenemedisin NO317628B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP93202523		1993-08-27
PCT/EP1994/002764 WO1995005815A1 (en)	1993-08-27	1994-08-19	Iontophoretic delivery of an antimigraine drug

Publications (3)

Publication Number	Publication Date
NO960769D0 NO960769D0 (no)	1996-02-26
NO960769L NO960769L (no)	1996-04-23
NO317628B1 true NO317628B1 (no)	2004-11-29

Family

ID=8214068

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19960769A NO317628B1 (no)	1993-08-27	1996-02-26	Iontoforetisk avlevering av en antimigrenemedisin

Country Status (28)

Country	Link
US (1)	US5674871A (pl)
EP (1)	EP0719138B1 (pl)
JP (1)	JP2921987B2 (pl)
KR (1)	KR100187632B1 (pl)
CN (1)	CN1096857C (pl)
AT (1)	ATE176591T1 (pl)
AU (1)	AU687876B2 (pl)
BR (1)	BR9407522A (pl)
CA (1)	CA2168449A1 (pl)
CZ (1)	CZ290473B6 (pl)
DE (1)	DE69416522T2 (pl)
DK (1)	DK0719138T3 (pl)
ES (1)	ES2129668T3 (pl)
FI (1)	FI960887A0 (pl)
GR (1)	GR3029920T3 (pl)
HR (1)	HRP940481A2 (pl)
HU (1)	HUT75062A (pl)
IL (1)	IL110784A (pl)
MY (1)	MY111022A (pl)
NO (1)	NO317628B1 (pl)
NZ (1)	NZ273304A (pl)
PH (1)	PH31437A (pl)
PL (1)	PL176290B1 (pl)
RU (1)	RU2166315C2 (pl)
SG (1)	SG50469A1 (pl)
SI (1)	SI9400333B (pl)
WO (1)	WO1995005815A1 (pl)
ZA (1)	ZA946533B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5853383A (en) *	1995-05-03	1998-12-29	Alza Corporation	Preparation for formulations for electrotransport drug delivery
US7137975B2 (en) *	2001-02-13	2006-11-21	Aciont, Inc.	Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
DE60227938D1 (de) *	2001-04-04	2008-09-11	Alza Corp	Transdermales verabreichungsgerät mittels elektrotransport mit einer kompatiblen antimikrobiellen reservoir-lösung
WO2002089803A1 (fr) *	2001-05-07	2002-11-14	Sankyo Company, Limited	Composition d'ionophorese
US7979117B2 (en) *	2001-10-24	2011-07-12	Power Paper Ltd.	Device and method for controlled delivery of active substance into the skin
ITMI20021200A1 (it) *	2002-06-03	2003-12-03	Gafitex S R L	Tessuto atto ad esplicare un effetto barriera contro campi magnetici ed elettromagnetici e/o effetti di metalloterapia
US8016811B2 (en) *	2003-10-24	2011-09-13	Altea Therapeutics Corporation	Method for transdermal delivery of permeant substances
US20050220439A1 (en) *	2004-03-19	2005-10-06	Carton Owen A	Interactive multimedia system and method
WO2007009462A2 (en) *	2005-07-15	2007-01-25	Region Hovedstaden V/Glostrup Hospital	Treatment of migraine and headaches
GB2430364A (en) *	2005-09-22	2007-03-28	Carl Ernest Alexander	Soft agar bolus for oral drug delivery
CN101472644B (zh) *	2006-04-13	2014-04-23	纽帕特公司	递送抗偏头痛化合物的透皮方法和系统
RU2352359C1 (ru) *	2007-10-24	2009-04-20	Общество с ограниченнной ответственностью "НПО Текстильпрогресс Инженерной Академии " (ООО "НПО Текстильпрогресс ИА")	Способ создания композиции для доставки лекарственного препарата в полости организма при заболеваниях

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4028125A1 (de) *	1990-01-17	1991-07-18	Klimke Markus	Applikationsvorrichtung fuer die geregelte dosierung verschiedener pharmakons mittels elektrischem strom zum perkutanen transport zur lokalen und systemischen therapie
WO1991015260A1 (en) *	1990-03-30	1991-10-17	Alza Corporation	Device and method for iontophoretic drug delivery
SI9300097B (en) *	1992-02-27	2001-12-31	Janssen Pharmaceutica Nv	(benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines

1994
- 1994-07-15 PH PH48643A patent/PH31437A/en unknown
- 1994-08-19 CN CN94193196A patent/CN1096857C/zh not_active Expired - Fee Related
- 1994-08-19 WO PCT/EP1994/002764 patent/WO1995005815A1/en not_active Ceased
- 1994-08-19 CZ CZ1996570A patent/CZ290473B6/cs not_active IP Right Cessation
- 1994-08-19 EP EP94926855A patent/EP0719138B1/en not_active Expired - Lifetime
- 1994-08-19 HU HU9600471A patent/HUT75062A/hu unknown
- 1994-08-19 SG SG1996002184A patent/SG50469A1/en unknown
- 1994-08-19 PL PL94313255A patent/PL176290B1/pl not_active IP Right Cessation
- 1994-08-19 JP JP7507338A patent/JP2921987B2/ja not_active Expired - Fee Related
- 1994-08-19 AU AU76542/94A patent/AU687876B2/en not_active Ceased
- 1994-08-19 RU RU96105930/14A patent/RU2166315C2/ru not_active IP Right Cessation
- 1994-08-19 DK DK94926855T patent/DK0719138T3/da active
- 1994-08-19 ES ES94926855T patent/ES2129668T3/es not_active Expired - Lifetime
- 1994-08-19 CA CA002168449A patent/CA2168449A1/en not_active Abandoned
- 1994-08-19 KR KR1019960700410A patent/KR100187632B1/ko not_active Expired - Fee Related
- 1994-08-19 BR BR9407522A patent/BR9407522A/pt not_active Application Discontinuation
- 1994-08-19 DE DE69416522T patent/DE69416522T2/de not_active Expired - Fee Related
- 1994-08-19 NZ NZ273304A patent/NZ273304A/en unknown
- 1994-08-19 US US08/586,700 patent/US5674871A/en not_active Expired - Fee Related
- 1994-08-19 AT AT94926855T patent/ATE176591T1/de not_active IP Right Cessation
- 1994-08-25 IL IL11078494A patent/IL110784A/xx not_active IP Right Cessation
- 1994-08-25 MY MYPI94002234A patent/MY111022A/en unknown
- 1994-08-26 SI SI9400333A patent/SI9400333B/sl not_active IP Right Cessation
- 1994-08-26 HR HR93.202.523.2A patent/HRP940481A2/hr not_active Application Discontinuation
- 1994-08-26 ZA ZA946533A patent/ZA946533B/xx unknown
1996
- 1996-02-26 NO NO19960769A patent/NO317628B1/no unknown
- 1996-02-26 FI FI960887A patent/FI960887A0/fi not_active Application Discontinuation
1999
- 1999-04-07 GR GR990401012T patent/GR3029920T3/el unknown

Also Published As

Publication number	Publication date
FI960887A7 (fi)	1996-02-26
HUT75062A (en)	1997-03-28
WO1995005815A1 (en)	1995-03-02
DK0719138T3 (da)	1999-09-20
JP2921987B2 (ja)	1999-07-19
DE69416522T2 (de)	1999-09-23
HU9600471D0 (en)	1996-04-29
CZ290473B6 (cs)	2002-07-17
AU687876B2 (en)	1998-03-05
NO960769D0 (no)	1996-02-26
CN1096857C (zh)	2002-12-25
JPH09501180A (ja)	1997-02-04
SI9400333B (sl)	2002-02-28
AU7654294A (en)	1995-03-21
FI960887A0 (fi)	1996-02-26
ATE176591T1 (de)	1999-02-15
PL176290B1 (pl)	1999-05-31
SG50469A1 (en)	1998-07-20
MY111022A (en)	1999-07-31
PH31437A (en)	1998-11-03
SI9400333A (en)	1995-04-30
PL313255A1 (en)	1996-06-24
CA2168449A1 (en)	1995-03-02
IL110784A0 (en)	1994-11-11
NO960769L (no)	1996-04-23
BR9407522A (pt)	1997-01-07
CZ57096A3 (en)	1996-08-14
ZA946533B (en)	1996-02-26
IL110784A (en)	1999-05-09
EP0719138B1 (en)	1999-02-10
ES2129668T3 (es)	1999-06-16
DE69416522D1 (de)	1999-03-25
RU2166315C2 (ru)	2001-05-10
EP0719138A1 (en)	1996-07-03
HRP940481A2 (en)	1997-08-31
KR100187632B1 (ko)	1999-06-01
GR3029920T3 (en)	1999-07-30
US5674871A (en)	1997-10-07
NZ273304A (en)	1997-02-24
CN1129905A (zh)	1996-08-28

Publication	Publication Date	Title
JPH0688912B2 (ja)	1994-11-09	医薬品の局部投与における電流１００μＡ以上のイオン浸透療法に適した経皮流量向上性医薬組成物
NO317628B1 (no)	2004-11-29	Iontoforetisk avlevering av en antimigrenemedisin
Fang et al.	1999	Evaluation of transdermal iontophoresis of enoxacin from polymer formulations: in vitro skin permeation and in vivo microdialysis using Wistar rat as an animal model
JP2002525307A (ja)	2002-08-13	ピペリジン誘導体を含むイオントフォレーゼ装置
US7596407B2 (en)	2009-09-29	Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
JP5116482B2 (ja)	2013-01-09	イオントフォレーシス用製剤
BR112020010146A2 (pt)	2020-10-13	composição frigoestável para fornecimento transdérmico iontoforético de um composto de triptano
RU2371179C2 (ru)	2009-10-27	Чрескожное введение соединений пиперазинил-2 (3н)-бензоксазолона посредством электрофореза
EP2874693A1 (en)	2015-05-27	Electric-field assisted administration of tapentadol
JP2012158538A (ja)	2012-08-23	ゲル状外用剤
KR20070012432A (ko)	2007-01-25	피페라지닐-2(3ｈ)-벤즈옥사졸론 화합물의 경피이온삼투요법적 전달
JPS62126138A (ja)	1987-06-08	イオントフオレ−ゼ生体電極用基剤組成物
HK1147692A (en)	2011-08-19	Composition for transdermal delivery of cationic active agents
HK1147692B (en)	2018-04-06	Composition for transdermal delivery of cationic active agents
HK1098048B (en)	2011-02-25	Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds